Abiopharma

🔍 Finn Patrick John (Executive)

Company: Twist Bioscience Corp (TWST)

Report Date: 2026-01-13

Detailed Transactions and Holdings:

• Acquired 3,279 shares of Common Stock at $8.82 per share (Direct)
  Date: 2026-01-13 | Code: M | equity_swap_involved: false | shares_owned_after: 336,162.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 23,279 shares of Common Stock at $40.0 per share (Direct)
  Date: 2026-01-13 | Code: S | equity_swap_involved: false | shares_owned_after: 312,883.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,279 shares of Stock Option (right to buy) at $8.82 per share (Derivative)
  Date: 2026-01-13 | Code: M | Expires: 2027-09-28 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025.
• F2: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.